Drug intelligence / Profile preview

Lactiplantibacillus rhamnosus NBM17-4

Development stage: Preclinical
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactiplantibacillus rhamnosus NBM17-4 is a specific probiotic bacterial strain isolated from the feces of healthy Korean adults. It has demonstrated potential anti-diabetic effects in preclinical studies, particularly by improving insulin sensitivity and pancreatic function while reducing liver steatosis in animal models of type 2 diabetes (T2D). The mechanism appears to involve upregulation of interleukin-22 (IL-22), which enhances metabolic health parameters. This strain is being investigated as a candidate for both therapeutic treatment and prevention of T2D and other metabolic diseases such as hyperlipidemia[1][2][6]. It is not currently known to be marketed under any brand name.

Targets

IL22 (Interleukin 22)

Beyond the preview

Go deeper on Lactiplantibacillus rhamnosus NBM17-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactiplantibacillus rhamnosus NBM17-4.

Explore the full profile